Testosterone Lawsuit News: Physicians Calling For More Research on Testosterone Treatment Drugs

Print

Testosterone Lawsuit News Has Doctors Seeking Answers and Call for Better Research Into The Cardiac Risks of Testosterone Treatment Drugs Like AndroGel, AndroDerm and Testim.

Testosterone-Lawsuits-AndroGel-Testim-Androderm-Lawyer-Wright-and-Schulte-LLCWith the safety of low testosterone treatment therapy coming into question along with pending testosterone lawsuits in Louisiana and Illinois alleging the prescription medication causes heart attacks, strokes and other serious physical complications, physicians are calling for more and better safety research on the testosterone therapy prescription medications such as AndroGel, Testim, and AndroDerm used to treat low testosterone. There are currently more than 50 testosterone lawsuits pending in U.S. District Court, Eastern District of Louisiana. (In Re: Testosterone Products Liability Litigation, No. 42, JPML), and in in the U.S. District Court, Northern District of Illinois (In Re: AndroGel Product Liability Litigation, MDL Docket No. 36).

The firm continues to speak with men who believe they have suffered strokes, heart attacks or other cardiac events due to testosterone treatment drugs like AndroGel and Testim. Free testosterone lawsuit case evaluations are available by calling 1-800-399-0795 or you can visit yourlegalhelp.com.

The Los Angeles Times is reported that doctors find research on testosterone therapy inconclusive and that leaves them uncertain about how to treat hypogonadism, also known as ‘Low T.’ An endocrinologist at the University of Washington recommended that researchers launch large and randomized clinical trials on testosterone replacement therapy and give some men low testosterone treatment and give others a placebo, then follow both groups for several years.

The LA Times further reported that studies on testosterone replacement therapy are also coming into question, including one published in November 2013 in the Journal of the American Medical Association (JAMA). The study suggested that men who went through an artery-clearing procedure and took testosterone treatment were 30 percent more likely to suffer a heart attack, stroke or death compared to men who did not take prescription testosterone medication. The LA Times article stated that JAMA came under fire by a group of doctors and medical organizations who claimed the authors’ conclusions were weakened by “gross data mismanagement” and called for the medical journal to retract the study. In response to the criticism, the authors’ admitted that their determination for increased risk was based on statistical estimates and not raw data. The raw data, according to the article, showed men who took prescription testosterone medication were less likely to have a cardiovascular event than the group that did not have testosterone treatment.
[westhawaiitoday.com/news/nation-world-news/testosterone-physicians-call-more-and-better-safety-research]

The November 2013 JAMA study was one of two studies that prompted the U.S. Food & Drug Administration (FDA) to reassess the potential health risks associated with low testosterone treatment medication. The FDA cited the observational study in its safety announcement in January 2014 and revealed that it was launching an investigation into whether men who take FDA-approved testosterone medication run the risk of having a stroke, heart attack or death. In addition to the JAMA study, which focused on older men in the U.S. Veterans Affairs health system, the FDA cited another observational study that suggested men over 65 and younger men who had a history of heart disease, had an increased risk of heart attack if they took prescription testosterone medication. According to the FDA, the agency only approves testosterone products for men who have no or low testosterone levels along with an underlying medical condition. The FDA stated in its safety communication that it has not come to the conclusion that testosterone replacement therapy increases the risk of stroke, heart attack and death, but will continue to review studies and available data and announce its conclusions after completing its evaluation.
[fda.gov/Drugs/DrugSafety/ucm383904.htm?utm_source=rss&utm_medium=rss&utm_campaign=fda-evaluating-risk-of-stroke-heart-attack-and-death-with-fda-approved-testosterone-products]

Meanwhile, court records indicate that testosterone lawsuits involving AndroGel, Testim, and Androderm continue to be filed on behalf of men who allege in their complaints that they suffered heart attacks, strokes and other serious cardiovascular problems after taking the prescription low testosterone medication. According to court documents, plaintiffs involved in complaints involving the low testosterone medication AndroGel, have asked the U.S. Judicial Panel on Multidistrict Litigation (JPML) to transfer and consolidate all pending AndroGel lawsuits to the U.S. District Court, Northern District of Illinois for coordinated pretrial proceedings. According to the March 28, 2014, brief to the JMPL, at least 38 AndroGel lawsuits have been filed across the country, with the majority being filed in U.S. District Court, Northern District of Illinois. (In Re: AndroGel Product Liability Litigation, MDL Docket No. 36)

Court records also show a similar brief regarding testosterone replacement therapy lawsuits has been filed by plaintiffs in Louisiana to the JPML, asking the judicial panel to transfer at least 50 low testosterone therapy complaints to the U.S. District Court, Eastern District of Louisiana. (In Re: Testosterone Products Liability Litigation, No. 42, JPML) Plaintiffs in these lawsuits allege they have suffered heart attacks, strokes and other serious complications from taking such low testosterone medication as AndroGel, AndroDerm, Axiron, Fortesta, Delatestryl, Straint, Depo-Testosterone and Testopel. (In Re: Testosterone Products Liability Litigation, No. 42, JPML) The JPML has scheduled a hearing on May 29, 2014, in Chicago, to hear oral arguments on the motion to transfer the testosterone cases to the federal court in Illinois. The JPML, however, did not indicate whether it would entertain the motion to transfer the low testosterone cases to the Louisiana federal court.

About Wright & Schulte LLC And Filing A Testosterone Lawsuit
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free testosterone lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.